Skip to content

Interest Income at other companies

ALN
Alnylam PharmaceuticalsALNY
$26.6M-7.2%
Septerna, Inc. logo
Septerna, Inc.SEPN
$5.03M+12.8%
Regenxbio logo
RegenxbioRGNX
$2M-19.9%
Opko Health logo
Opko HealthOPK
$3.01M-35.8%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$1.21M+104%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$2.07M-23.4%

Other financials

Income statement

See full
Operating income-$27.3M-49.2%
Net income-$25.2M-58.7%
EPS (diluted)-$1.34-44.1%

Balance sheet

See full
Cash & equivalents$236.9M-22.8%
Total debt$4.9M+86.1%
Total equity$230.4M-23.5%
Total assets$246.6M-21.7%

Cash flow

See full
Operating cash flow-$18.4M-40.7%
CapEx$19.0K-29.6%
Free cash flow-$18.4M-40.6%

Valuation

See full
Market cap$585.51M+58.3%
Enterprise value$353.51M+438%

Returns & leverage

See full
Return on equity-31.4%
Debt / equity0.0×
Current ratio18.5×-4.4×

Where this comes from

Reported directly by Tectonic Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The official record: Tectonic Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tectonic Therapeutics's interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tectonic Therapeutics's interest income?
Tectonic Therapeutics (TECX) reported interest income of $2.18M in Q1 2026.
How has Tectonic Therapeutics's interest income changed year-over-year?
Tectonic Therapeutics's interest income decreased by 10.8% year-over-year, from $2.44M to $2.18M.
What is the long-term trend for Tectonic Therapeutics's interest income?
Over 3 years (2021 to 2025), Tectonic Therapeutics's interest income has grown at a 269.5% compound annual growth rate (CAGR), from -$224K to $11.3M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.